key: cord-0908637-xmoajn0o authors: Penetra, Stephanie L.S.; da Silva, Michele F.B.; Resende, Paola; Pina-Costa, Anielle; Santos, Heloisa F.P.; Guaraldo, Lusiele; Calvet, Guilherme A.; Ogrzewalska, Maria; Arantes, Ighor; Zukeram, Ketiuce; de Araújo, Mia F.; Lima, Ana Beatriz Machado; Lopes, Renata Serrano; Lira-Silva, Larissa R.; Moraes, Isabella V.; Wakimoto, Mayumi D.; Fuller, Trevon L.; Gabaglia, Claudia Raja; Espíndola, Otávio M.; Bonaldo, Myrna C.; Daniel-Ribeiro, Cláudio Tadeu; Whitworth, Jimmy; Smith, Chris; Nielsen-Saines, Karin; Pauvolid-Correa, Alex; Siqueira, Marilda M.; Brasil, Patricia title: Post-acute COVID-19 syndrome after reinfection and vaccine breakthrough by the SARS-CoV-2 Gamma variant in Brazil date: 2021-10-29 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2021.10.048 sha: dc6679a42c1e7090928a4f9113d597b284713489 doc_id: 908637 cord_uid: xmoajn0o We describe a case of prolonged COVID-19 caused by the SARS-CoV-2 Gamma variant in a fully vaccinated healthcare worker, 387 days after an infection caused by lineage B.1.1.33. Infections were confirmed by whole-genome sequencing and corroborated by the detection of neutralizing antibodies in convalescent serum samples. Considering the permanent exposure of this healthcare worker to SARS-CoV-2, the waning immunity after the first infection, the low efficacy of the inactivated vaccine at preventing COVID-19, the immune escape of the Gamma variant (VOC), and the burden of post-COVID syndrome, this individual would have benefited from an additional dose of a heterologous vaccine. With the ongoing pandemic, long-term manifestations are being observed in COVID-19 recovered patients. This is defined as Post-acute COVID-19 syndrome, characterized by the persistence of symptoms after 4 weeks from the onset of the disease. It presents a broad spectrum of manifestations, which may encompass all organs and systems and nonspecific symptoms (Nalbandian et al., 2021) . The diagnosis is often hard to establish, the exact underlying pathophysiology mechanisms remain unknown (Greenhalgh et al., 2020) , and the frequency of occurrence is not established. As of August 2021, Brazil has the third-highest number of cumulative cases of COVID-19 worldwide (Oswaldo Cruz Foundation, 2021) . In December 2020, the first confirmed case of reinfection was reported in the country, followed by several other cases, mostly caused by the Gamma variant of concern (VOC) among unvaccinated individuals (Brazilian Ministry of Health, 2021). Brazil's vaccination campaign started in January 2021, with adsorbed 4 (inactivated) SARS-CoV-2 vaccine (CoronaVac-Sinovac/Butantan), administered in a twodose schedule, with doses separated by a 28 day interval (Oswaldo Cruz Foundation, 2021) . CoronaVac was the first vaccine available in Brazil, when healthcare workers (HCW) immunization was prioritized. By the end of August 2021, 27% of the country's population of 230 million had been fully vaccinated. Effectiveness of CoronaVac was around 65.9% for the prevention of COVID-19 in Chile (Jara et al., 2021) and 49.4% (95% CI 13.2 to 71.9) effective in the prevention of COVID-19 in HCW, in a setting of high prevalence of the Gamma VOC in Manaus, Brazil (Hitchings et al., 2021) . These results were similar to that of A healthy 43-year-old male HCW presented with fever, headache, rhinorrhea, and dry cough on April 5, 2020. Clinical manifestations disappeared after 14 days, and no hospitalization was necessary. COVID-19 was confirmed by RT-PCR of a nasopharyngeal 5 sample, as previously described (Konrad et al., 2020) . The SARS-CoV-2 B.1.1.33 lineage was identified by whole-genome sequencing. Briefly, the SARS-CoV-2 genome was assembled using established Illumina protocols (Resende et al., 2020) . Spike protein specific immunoglobulin G (anti-S IgG) was under the detectable range five months after the initial infection (September 9, 2020), but still present two months after the second dose of vaccine (April 27, 2021) and ten days after reinfection (May 6, 2021) ( Figure 1.B) . The humoral response to SARS-CoV-2 after reinfection was confirmed by a highly specific plaque reduction neutralization test (PRNT 90 ) for SARS-CoV-2. Inactivated serum samples presented high neutralizing antibodies (Nabs) titers for B.1.1.33 (320), Gamma (320), and Delta (160). This case illustrates that even after complete vaccination the continuous exposure of HCWs to SARS-CoV-2 can lead to breakthrough infection. Furthermore, unlike the first infection, the clinical presentation of SARS-CoV-2 upon reinfection was characterized by persistent neurological symptoms. Our data suggest rapid waning of binding antibodies by the absence or low levels of anti-S IgG after the infection with B.1.1.33, but presence of highly specific Nabs for B.1.1.33, Delta and Gamma VOCs, after complete vaccination following a second episode of COVID-19. Whether the HCW developed Nabs after full immunization with CoronaVac remains unknown. Usually, individuals with pre-existing immunity develop uniformly high neutralizing antibody responses (Reynolds et al., 2021) . Although it is not clear which qualitative and quantitative parameters could be used as an adequate correlate of protection and its duration, this HCW was not protected against reinfection. We hypothesize that this is probably due to absent post-infection virus neutralizing activity, a short-lived humoral immune response, and the circulation of new variants capable of escaping immune responses generated by the first infection (Fintelman-Rodrigues et al., 2021) , and by the immunity rendered by two doses of CoronaVac. Although Nab appears to protect against symptomatic infection, the minimum titers necessary for conferring immunity to SARS-CoV-2 are a topic of ongoing research. The patient had no known comorbidities. The only factor that could explain the multiple episodes of COVID was his permanent exposure to SARS-CoV-2. His reinfection occurred more than a year after the primary infection, time expected for waning of protection following natural infection by SARS-CoV-2 (Hall et al., 2021) . As expected in vaccinees, the patient did not develop acute critical illness, confirming the efficacy of CoronaVac in 7 reducing the risk of severe disease and death at a time when the Gamma variant accounted for 96% of circulating genotyped SARS-CoV-2 specimens (Hitchings et al., 2021) . Nevertheless, the patient required long-term specialized care because of post-COVID-19 syndrome. As of August 2021, social distancing measures were relaxed and vaccinated individuals have engaged more frequently in social activities, increasing their risk of exposure to SARS-CoV-2 and breakthrough infections globally. Moreover, it is of concern that vaccines currently being used in Brazil, including CoronaVac, barely prevent infection and transmission, contributing to the persistence of the pandemic, particularly in the current scenario of predominantly highly transmissible Delta VOC, the prevalence of which has increased from 48% in July to 86% in August 2021. It is thus highly advisable that SARS-CoV-2 surveillance and intervention programs aimed at reducing viral exposure continue until an adequate proportion of the population is fully vaccinated, especially considering the emergence of new VOC that may compromise vaccine efficacy. Considering the permanent exposure of this healthcare worker to SARS-CoV-2, the waning immunity of first infection, the low efficacy of inactivated vaccine in the prevention of COVID-19, the immune escape of Gamma variant (VOC), and the burden of post-COVID syndrome, this individual would have benefited from an additional dose of a heterologous vaccine. In the epidemiological setting of low immunization rates and high transmission rates of SARS-CoV-2, the breakthrough reinfection with a VOC in a HCW is particularly timely and may presage trends in reinfection and hospitalization across Latin America, as we enter the third year of the pandemic. As vaccine supply chain limitations ease, evidence-based decisions about boosting are urgently required. In addition, better understanding of immune factors potentially associated with persistence of COVID-19 symptoms might help the management of this condition. Brazilian Ministry of Health The effectiveness of Vaxzevria and CoronaVac vaccines: A nationwide longitudinal retrospective study of 61 million Brazilians (VigiVac-COVID19). medRxiv [Preprint Genetic Evidence and Host Immune Response in Persons Reinfected with SARS-CoV-2 Management of post-acute covid-19 in primary care New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0 SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant 10 Brazil: A test-negative case-control study Limited and short-lasting virus neutralizing titers induced by inactivated SARS-CoV-2 vaccine Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile Rapid establishment of laboratory diagnostics for the novel coronavirus SARS-CoV-2 in Bavaria Post-acute COVID-19 syndrome Institute of Scientific and Technological Communication and Information in Health. MonitoraCOVID-19 Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool SARS-CoV-2 genomes Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose Should a third booster dose be scheduled after two doses of CoronaVac? A single-center experience Timeline of SARS-CoV-2 P.1 Gamma reinfection case and antibody status. C & D Phylogenetic and temporal characterization of SARS-CoV-2 genomes recovered from primary infection and from reinfection episode. C. Maximum Likelihood tree (n = 189) constructed with IQ-TREE2 of Brazilian SARS-CoV-2 whole genome sequences (29,415 nts Delta (B.1.617.2), Gamma (P.1), Lambda (C.37) and Zeta (P.2) lineages have their statistical support (aLRT, average likelihood ration test) indicated in their corresponding branches. The three was rooted with a B lineage reference sequence from Time-scaled Bayesian MCC tree of whole genome sequences inferred with Beast 1.10 from Brazilian SARS-CoV-2 Gamma variant (n = 100). The reinfection sample and its MRCA (Most Recent Common Ancestor) are both highlighted by their shapes. The collection date and the date to which the MRCA was traced back to (alongside its 95% HPD interval) are both Recent Common Ancestor) of the reinfection genome was traced back to early This work was supported by MS/FNDCT/SCTIE/Decit [grants 402457/2020-9 and 403276/2020-9] Table) . We also appreciate the support of the Fiocruz COVID- The authors have indicated they have no potential conflicts of interest to disclose. The authors have indicated they have no financial relationships relevant to this article to disclose. This case is part of a cohort study of COVID-19 patients where immunity and genomic surveillance of SARS-CoV-2 are evaluated, with systematic collection of blood and respiratory tract samples. Informed consent was obtained from all the participants. The study 9 was approved by the Brazilian National Ethics Committee (CONEP) under register number 30639420.0.0000.5262.